secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001213900-23-018371
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Q4 net loss $39.0M; cash $102.3M; TARA-002 data expected Q2 2023
------------------------------------------------------------------------

- Net loss Q4 2022: $39.0M ($3.46 per share) vs $10.2M ($0.91) in Q4 2021; includes $29.5M goodwill impairment.
- Full year 2022 net loss $66.0M ($5.86 per share) vs $47.3M ($4.21) in 2021; R&D expense $16.8M, G&A $20.7M.
- Cash, equivalents, and marketable debt securities $102.3M as of Dec 31, 2022; expected to fund operations into 2025.
- Phase 1a data from ADVANCED-1 trial of TARA-002 in NMIBC expected in Q2 2023; Phase 2 trial in LMs to start 2H 2023.
- Prospective study of IV Choline Chloride in IFALD ongoing; results expected Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023018371/0001213900-23-018371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390023018371/ea174762-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-018371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer